MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Amantadine"

  • 2016 International Congress

    ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study

    R. Pahwa, C.M. Tanner, R.A. Hauser, P. Nausieda, D.D. Truong, K. Hull, P. Agarwal, R. Johnson, A.E. Ruby, N.L. McClure, M.J. Stempien (Kansas City, KS, USA)

    Objective: To investigate the efficacy and safety of ADS-5102 (amantadine HCl) extended release capsules 340 mg daily at bedtime for the treatment of levodopa-induced dyskinesia…
  • 2016 International Congress

    Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

    A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

    Objective: To examine the long-term effect of repeated boosts of intravenous amantadine in patients with PD with and without response fluctuations and dyskinesias. Background: Amantadine…
  • 2016 International Congress

    Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

    A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

    Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…
  • 2016 International Congress

    Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia

    N.G. Sokhibnazarov, F.K. Shermukhamedova (Tashkent, Uzbekistan)

    Objective: Aim of this study was to identify the degree of cognitive dysfunction in patients with subcortical Parkinsonian dementia, during the neuroprotective therapy. Background: Parkinson's…
  • 2016 International Congress

    Parkinson’s syndrome as possible manifestation of lamina quadrigemina tumor or inflammation

    N.M. Pavlyshyna, I.V. Khubetova (Odessa, Ukraine)

    Objective: Objective of this report is to discuss the case of Parkinson's syndrome (PS) in 22 y.o. patient on the background of the pathological process…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Carpal Tunnel Syndrome in Patients with Tremor
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Dropped head syndrome in parkinsonism: Two treatable etiologies not to miss
  • Decision-making process for opicapone’s bedtime regimen
  • Diaphragmatic dystonia in a patient that presents with Meige syndrome and disordered breathing
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley